KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Princess U Ogbogu, Florence Roufosse, Praveen Akuthota, Piotr Kuna, Matthieu Groh, Andreas Reiter, Akira Yokota, Salman H Siddiqui, Pim G N J Mutsaers, Bing Li, Paneez Khoury, Lila M Bahadori, Artur Bednarczyk, Gerben Bouma, Laura G Brooks, Jorge Ferreira, Hanna Grindebacke, Calvin N Ho, Priya Jain, Rebecca L Palmer, Maria L Jison, Amy D Klion, NATRON study group

Nat Med 32(6) 2017-2025

PMID41917160
PMCIDPMC13278967
DOI10.1038/s41591-026-04315-8
发表日期2026-03-31
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Benralizumab, an eosinophil-depleting anti-IL-5 receptor α antibody, has demonstrated efficacy in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis and shown promising results in hypereosinophilic syndrome (HES). NATRON was a randomized, double-blind placebo-controlled phase 3 study evaluating the efficacy and safety of benralizumab in FIP1L1::PDGFRA-negative HES. The primary endpoint was time to first HES flare. In total, 133 patients (median (range) age 51 (14-87) years, 62% female) were randomized (1:1) to receive benralizumab 30 mg every 4 weeks or placebo for 24 weeks, in addition to background therapy. Benralizumab significantly reduced the risk of first flare versus placebo (hazard ratio 0.35, 95% CI 0.18 to 0.69, P = 0.0024). Adverse events occurred in 64.2% and 66.7% of benralizumab- and placebo-treated patients, respectively. Benralizumab's safety was consistent with its known profile. These results demonstrate the efficacy and safety of add-on benralizumab in the treatment of HES. ClinicalTrials.gov identifier: NCT04191304 .

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Fig. 2. Time to first HES flare (primary endpoint). The time to first HES flare was analyzed using a stratified log-rank test (two-sided significance level of 0.05) adjusted for region. HR and 95% CIs were estimated using a Cox proportional hazards model with treatment group and region as covariates. For patients who did not experience a HES worsening/flare, the time to first HES worsening/flare was right censored at the end of the double-blind period corresponding to the earliest date of: the first benralizumab open-label dose, study day 183, the date of last contact and the data cutoff date. An HR < 1 favors benralizumab. Flare was defined as HES clinical manifestations or laboratory abnormalities that resulted in an increase/burst of OCS ≥10 mg day −1 prednisolone equivalent for at least 2 days or an increase or addition of new cytotoxic and/or immunosuppressive therapy or hospitalization.

Fig._2

Time to first HES flare

Fig. 2 · Panel Fig._2

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Fig._2 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

Fig. 3

Fig. 3. Key secondary endpoints. a , The proportion of patients with HES flares was analyzed using a logistic regression model with treatment group and region as covariates to estimate the OR and 95% CIs. This analysis included patients who withdrew from the study without having flares as an event; these patients were censored at the time of study withdrawal in the analysis of time to first flare. b , The number of HES flares (annualized rate) was analyzed using a negative binomial model with treatment group and region as covariates. The logarithm of follow-up time was used as an offset variable. Flare rates were estimated for each treatment group (error bars represent 95% CIs) and the RR and 95% CIs were calculated for benralizumab versus placebo. c , The time to first hematologic relapse (AEC ≥1,000 cells µl −1 ) was analyzed using a stratified log-rank test, adjusted for region. HR and 95% CIs were estimated using a Cox proportional hazards model with treatment group and region as covariates. Patients who did not experience hematologic relapse were right censored at the end of the double-blind period corresponding to the earliest date of: the first benralizumab open-label dose, study day 183, the date of last contact and the data cutoff date. d , The LS mean change from baseline to week 24 in PROMIS Fatigue scores was analyzed using a mixed model for repeated measures, with treatment group, baseline score, visit, region and treatment visit interaction as covariates. All available observations were included with no imputation for missing data, assuming missing data were missing at random. The standardized T -score range for Short Form 7a is from 29.4 to 83.2; higher scores indicate more severe fatigue. P values from week 4 to 20 are nominal. Hierarchical fixed sequence testing of key secondary endpoints was conducted in the order presented ( a – d ) at a two-sided significance level of 0.05. Error bars represent 95% CIs. Values of HR <1, OR <1, RR <1 and LS mean difference <0 favor benralizumab.

C

time to first hematologic relapse

Fig. 3 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Trial profile. The flow of patients through the study, from enrollment through to completion of the double-blind period. Q4W, every 4 weeks.
非 KM Figure